<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Through an immune-mediated graft-versus-<z:hpo ids='HP_0001909'>leukemia</z:hpo> effect, allogeneic hematopoietic stem cell transplantation (HSCT) affords durable clinical benefits for many patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Nonetheless, subjects with high-risk <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> or advanced <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> often relapse, underscoring the need to intensify <z:e sem="disease" ids="C1519680" disease_type="Disease or Syndrome" abbrv="">tumor immunity</z:e> within this cohort </plain></SENT>
<SENT sid="2" pm="."><plain>In preclinical models, allogeneic HSCT followed by vaccination with irradiated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells engineered to secrete GM-CSF generates a potent antitumor effect without exacerbating the toxicities of <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) </plain></SENT>
<SENT sid="3" pm="."><plain>To test whether this strategy might be similarly active in humans, we conducted a Phase I clinical trial in which high-risk <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> patients were immunized with irradiated, autologous, GM-CSF-secreting <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells early after allogeneic, nonmyeloablative HSCT </plain></SENT>
<SENT sid="4" pm="."><plain>Despite the administration of a calcineurin inhibitor as prophylaxis against GVHD, vaccination elicited local and systemic reactions that were qualitatively similar to those previously observed in nontransplanted, immunized <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid-tumor</z:e> patients </plain></SENT>
<SENT sid="5" pm="."><plain>While the frequencies of <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD were not increased, 9 of 10 subjects who completed vaccination achieved durable complete remissions, with a median follow-up of 26 months (range 12-43 months) </plain></SENT>
<SENT sid="6" pm="."><plain>Six long-term responders showed marked decreases in the levels of soluble NKG2D ligands, and 3 demonstrated normalization of cytotoxic lymphocyte NKG2D expression as a function of treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Together, these results establish the safety and immunogenicity of irradiated, autologous, GM-CSF-secreting <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell vaccines early after allogeneic HSCT, and raise the possibility that this combinatorial immunotherapy might potentiate graft-versus-<z:hpo ids='HP_0001909'>leukemia</z:hpo> in patients </plain></SENT>
</text></document>